GWP GW Pharm.

RNS Number:4456T
GW Pharmaceuticals PLC
22 March 2007





  GW and Otsuka Receive Hart-Scott-Rodino Clearance for Sativex(R) US License
                                   Agreement

22 March 2007:  GW Pharmaceuticals plc and Otsuka Pharmaceutical Co. Ltd today
announce that they have each received early termination by the United States
Federal Trade Commission and the Antitrust Division of the United States
Department of Justice of the required waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 with respect to the development and license
agreement announced on 14 February 2007 granting Otsuka exclusive rights to
develop and market Sativex(R), GW's lead product, in the United States.  With
the grant of HSR clearance, GW and Otsuka have now received the approval of the
U.S. antitrust authorities necessary to close the transaction.

On 14 February 2007, GW and Otsuka announced that they had entered into a major
long term strategic cannabinoid alliance.  The relationship has commenced with
the grant to Otsuka of an exclusive license to develop and market Sativex in the
U.S.  The companies are also in detailed discussions with a view to entering
into a cannabinoid research collaboration in the field of Central Nervous System
(CNS) disorders and cancer treatment in order to research, develop and
commercialize a range of other early stage cannabinoid product opportunities.


Enquiries:
For GW:
                  GW Pharmaceuticals plc                   Tel: + 44 1980 557000
                  Dr Geoffrey Guy, Chairman
                  Justin Gover, Managing Director

                  Financial Dynamics                       Tel: +44 20 7831 3113
                  David Yates, Nicola Daley
For Otsuka:
                  US Enquiries
                  Debbie Kaufmann                           Tel: +1 240 683 3568
                  Europe Enquiries
                  Alison Ross                             Tel: +44 1895 207 7122
                  Japan Enquiries
                  Hideki Shirai                             Tel: +81 3 3292 0021


Notes to Editors

About Otsuka Pharmaceutical Co., Ltd

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with
the mission statement: "Otsuka - people creating new products for better health
worldwide."  Otsuka researches, develops, manufactures and markets innovative,
original products, focusing its core businesses on pharmaceutical products for
the treatment of disease and consumer products for the maintenance of everyday
health. The Otsuka Pharmaceutical Group comprises 87 companies and employs
approximately 27,000 people in 17 countries and regions worldwide.  Otsuka and
its consolidated subsidiaries earned US $6.8 billion in consolidated annual
revenues in fiscal 2005. The Group has R&D facilities in Japan (Osaka and
Tokushima), EU (Frankfurt) and US (Rockville, MD). Its commercial operations are
headquartered in US (Rockville, MD and Princeton, NJ), EU (UK) and Japan
(Tokyo). For additional information, visit www.otsuka-global.com


About GW

GW was founded in 1998 and listed on the AiM, a market of the London Stock
Exchange, in June 2001. Operating under license from the UK Home Office, the
company researches and develops cannabinoid pharmaceutical products that
alleviate pain and other neurological symptoms in patients who suffer from
serious ailments. GW has assembled a team of over 100 scientists with extensive
experience in developing both plant-based prescription pharmaceutical products
and medicines containing controlled substances. GW occupies a world leading
position in cannabinoids and has developed an extensive international network of
the most prominent scientists in the field. GW has to date entered into two
additional Sativex license agreements - with Bayer HealthCare in the UK and
Canada, and with Almirall in Europe (ex-UK). These agreements together provide
payments to GW totaling up to #79m ($156m) as well as significant long term
supply price provisions. For further information, please visit www.gwpharm.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRPUUAAWUPMGAG

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024